Publications
160 results found
Ward RJ, Lallemand F, de Witte P, et al., 2011, Anti-inflammatory actions of a taurine analogue, ethane β-sultam, in phagocytic cells, <i>in vivo</i> and <i>in vitro</i>, BIOCHEMICAL PHARMACOLOGY, Vol: 81, Pages: 743-751, ISSN: 0006-2952
- Author Web Link
- Cite
- Citations: 15
Broom L, Marinova-Mutafchieva L, Sadeghian M, et al., 2011, Neuroprotection by the selective iNOS inhibitor GW274150 in a model of Parkinson disease, FREE RADICAL BIOLOGY AND MEDICINE, Vol: 50, Pages: 633-640, ISSN: 0891-5849
- Author Web Link
- Cite
- Citations: 72
Crichton RR, Dexter DT, Ward RJ, 2011, Brain iron metabolism and its perturbation in neurological diseases, JOURNAL OF NEURAL TRANSMISSION, Vol: 118, Pages: 301-314, ISSN: 0300-9564
- Author Web Link
- Cite
- Citations: 182
Ward RJ, Crichton RR, Taylor DL, et al., 2011, Iron and the immune system, JOURNAL OF NEURAL TRANSMISSION, Vol: 118, Pages: 315-328, ISSN: 0300-9564
- Author Web Link
- Cite
- Citations: 83
Nalls MA, Plagnol V, Hernandez DG, et al., 2011, Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies, LANCET, Vol: 377, Pages: 641-649, ISSN: 0140-6736
- Author Web Link
- Cite
- Citations: 697
Dexter DT, Statton SA, Whitmore C, et al., 2011, Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration, JOURNAL OF NEURAL TRANSMISSION, Vol: 118, Pages: 223-231, ISSN: 0300-9564
- Author Web Link
- Cite
- Citations: 108
Dexter D, Allen R, Gillies G, et al., 2010, Stress is a Predisposing Factor for Parkinson's Disease in Males but Not Females, MOVEMENT DISORDERS, Vol: 25, Pages: S619-S619, ISSN: 0885-3185
Evans J, Durrenberger PF, Reynolds R, et al., 2010, Promyelocytic Leukaemia Protein Inclusion Bodies in Parkinsonian Astrocytes, MOVEMENT DISORDERS, Vol: 25, Pages: S628-S628, ISSN: 0885-3185
Aitchison K, Datla K, Rooprai H, et al., 2010, Regional distribution of clomipramine and desmethylclomipramine in rat brain and peripheral organs on chronic clomipramine administration, JOURNAL OF PSYCHOPHARMACOLOGY, Vol: 24, Pages: 1261-1268, ISSN: 0269-8811
- Author Web Link
- Cite
- Citations: 14
Pienaar IS, Dexter DT, Burkhard PR, 2010, Mitochondrial proteomics as a selective tool for unraveling Parkinson's disease pathogenesis, EXPERT REVIEW OF PROTEOMICS, Vol: 7, Pages: 205-226, ISSN: 1478-9450
- Author Web Link
- Cite
- Citations: 17
Durrenberger PF, Fernando S, Kashefi SN, et al., 2010, Effects of Antemortem and Postmortem Variables on Human Brain mRNA Quality: A BrainNet Europe Study, JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, Vol: 69, Pages: 70-81, ISSN: 0022-3069
- Author Web Link
- Cite
- Citations: 130
Chan H, Paur H, Vernon AC, et al., 2010, Neuroprotection and Functional Recovery Associated with Decreased Microglial Activation Following Selective Activation of mGluR2/3 Receptors in a Rodent Model of Parkinson's Disease, Parkinson's Disease, Vol: 2010, Pages: 1-12
<jats:p>Clinical trials have demonstrated positive proof of efficacy of dual metabotropic glutamate receptor 2/3 (mGluR2/3) agonists in both anxiety and schizophrenia. Importantly, evidence suggests that these drugs may also be neuroprotective against glutamate excitotoxicity, implicated in the pathogenesis of Parkinson's disease (PD). However, whether this neuroprotection also translates into functional recovery is unclear. In the current study, we examined the neuroprotective efficacy of the dual mGluR2/3 agonist, 2<jats:italic>R</jats:italic>,4<jats:italic>R</jats:italic>-4-aminopyrrolidine-2,4-dicarboxylate (2<jats:italic>R</jats:italic>,4<jats:italic>R</jats:italic>-APDC), and whether this is accompanied by behavioral recovery in a rodent 6-hydroxydopamine (6-OHDA) model of PD. We now report that delayed post lesion treatment with 2<jats:italic>R</jats:italic>,4<jats:italic>R</jats:italic>-APDC (10 nmol), results in robust neuroprotection of the nigrostriatal system, which translated into functional recovery as measured by improved forelimb use asymmetry and reduced (+)-amphetamine-induced rotation compared to vehicle treated animals. Interestingly, these beneficial effects were associated with a decrease in microglial markers in the SNc, which may suggest an antiinflammatory action of this drug.</jats:p>
Ward RJ, Colivicchi MA, Allen R, et al., 2009, Neuro-inflammation induced in the hippocampus of 'binge drinking' rats may be mediated by elevated extracellular glutamate content., J Neurochem, Vol: 111, Pages: 1119-1128
The neuropathological and immune changes induced in the brain by 'binge drinking' have been investigated in a rat model. Evidence of neuro-inflammation was identified in the 'binge drinking' rat model of alcohol abuse after 3 weeks of administration of 2 or 3 g/kg ethanol (EtOH), three times per day for two consecutive days, followed by 5 days of abstinence: Firstly, alveolar macrophages, isolated from these animals, showed significant increases in inducible nitric oxide synthase, as assayed by nitrite release, both before and after lipopolysaccaharide stimulation. Secondly, significant numbers of activated microglia were present in the dentate gyrus region of the hippocampus of the 'binge drinking' model, after major histocompatibility complex class II staining, by comparison with the control. Microdialysis studies in the ventral hippocampus identified a significant increase in the basal extracellular concentration of glutamate, in both the 2 and 3 g/kg administered 'binge drinking' rats. In contrast, no changes in the hippocampal extracellular concentrations, of GABA and taurine, or the dopamine and serotonin metabolites were observed under basal conditions. A further dose of EtOH induced a significant decrease in the concentrations of both 3,4-dihydroxyphenylacetic acid and 5-hydroxyindoleacetic acid, whereas glutamate, taurine and GABA levels were unaffected. There was no evidence that EtOH preference was initiated by the 'binge drinking' regimen. Our results suggest that the possible toxicity associated with 'binge drinking' maybe directed by the elevated glutamate levels, which in turn, activate phagocytic cells to release their inflammatory cytokines and chemokines, ultimately leading to neuro-inflammation.
Marinova-Mutafchieva L, Sadeghian M, Broom L, et al., 2009, Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's disease, JOURNAL OF NEUROCHEMISTRY, Vol: 110, Pages: 966-975, ISSN: 0022-3042
- Author Web Link
- Cite
- Citations: 155
Durrenberger PF, Fernando S, Kashefi SN, et al., 2008, Microarray gene expression analysis of common pathogenetic mechanisms in neurodegenerative diseases, BrainNet Europe 2nd International Conference on Human Brain Tissue Research, Publisher: SPRINGER WIEN, Pages: 1730-1730, ISSN: 0300-9564
Goldring K, McGuinness L, Vontell RT, et al., 2008, Clinicopathological classification of the first 100 cases donated to the UK PDS Tissue Bank at Imperial College, BrainNet Europe 2nd International Conference on Human Brain Tissue Research, Publisher: SPRINGER WIEN, Pages: 1724-1724, ISSN: 0300-9564
McGuinness L, Vontell RT, Dexter DT, et al., 2008, Optimisation of immunohistochemistry for visualising abnormal protein deposition in neurodegenerative disorders, BrainNet Europe 2nd International Conference on Human Brain Tissue Research, Publisher: SPRINGER WIEN, Pages: 1726-1726, ISSN: 0300-9564
Durrenberger PF, Fernando S, Kashefi SN, et al., 2008, Gene expression profiling of grey matter lesions in secondary progressive multiple sclerosis, 13th Annual Meeting of the Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/24th Congress of the European-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis/5th Congress of the Latin-Amer-Comm-for-Treatment-and-Res-in-Multiple-Sclerosis, Publisher: SAGE PUBLICATIONS LTD, Pages: S270-S270, ISSN: 1352-4585
Ward RJ, Lallemand F, de Witte P, et al., 2008, Neurochemical pathways involved in the protective effects of nicotine and ethanol in preventing the development of Parkinson's disease: Potential targets for the development of new therapeutic agents, PROGRESS IN NEUROBIOLOGY, Vol: 85, Pages: 135-147, ISSN: 0301-0082
- Author Web Link
- Cite
- Citations: 26
Crichton RR, Dexter DT, Ward RJ, 2008, Metal based neurodegenerative diseases - From molecular mechanisms to therapeutic strategies, COORDINATION CHEMISTRY REVIEWS, Vol: 252, Pages: 1189-1199, ISSN: 0010-8545
- Author Web Link
- Cite
- Citations: 227
Bell JE, Alafuzoff I, Al-Sarraj S, et al., 2008, Management of a twenty-first century brain bank: experience in the BrainNet Europe consortium, ACTA NEUROPATHOLOGICA, Vol: 115, Pages: 497-507, ISSN: 0001-6322
- Author Web Link
- Cite
- Citations: 86
Vernon AC, Croucher MJ, Dexter DT, 2008, Additive neuroprotection by metabotropic glutamate receptor subtype-selective ligands in a rat Parkinson's model, NEUROREPORT, Vol: 19, Pages: 475-478, ISSN: 0959-4965
- Author Web Link
- Cite
- Citations: 19
Vernon AC, Zbarsky V, Datla KP, et al., 2007, Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity <i>in vivo</i>, JOURNAL OF NEUROCHEMISTRY, Vol: 103, Pages: 1075-1091, ISSN: 0022-3042
- Author Web Link
- Cite
- Citations: 49
Datla KP, Zbarsky V, Rai D, et al., 2007, Short-term supplementation with plant extracts rich in flavonoids protect nigrostriatal Dopaminergic neurons in a rat model of Parkinson's Disease, JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION, Vol: 26, Pages: 341-349, ISSN: 0731-5724
- Author Web Link
- Cite
- Citations: 53
Slonimsky A, Hickey L, Christian L, et al., 2007, Expression of gamma-synuclein in Parkinson's disease, 108th Annual Meeting of the British-Neuopathological-Society, Publisher: BLACKWELL PUBLISHING, Pages: 256-256, ISSN: 0305-1846
Moran LB, Croisier E, Duke DC, et al., 2007, Analysis of alpha-synuclein, dopamine and parkin pathways in neuropathologically confirmed Parkinsonian nigra, ACTA NEUROPATHOLOGICA, Vol: 113, Pages: 253-263, ISSN: 0001-6322
- Author Web Link
- Cite
- Citations: 35
McArthur S, Murray HE, Dhankot A, et al., 2007, Striatal susceptibility to a dopaminergic neurotoxin is independent of sex hormone effects on cell survival and DAT expression but is exacerbated by central aromatase inhibition, JOURNAL OF NEUROCHEMISTRY, Vol: 100, Pages: 678-692, ISSN: 0022-3042
- Author Web Link
- Cite
- Citations: 45
Vernon AC, Zbarsky V, Datla KP, et al., 2007, Selective activation of group III metabotropic glutamate receptors by L-(+)-2-amino-4-phosphonobutryic acid protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo, JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, Vol: 320, Pages: 397-409, ISSN: 0022-3565
- Author Web Link
- Cite
- Citations: 32
Moran LB, Duke DC, Croisier E, et al., 2006, Whole genome expression profiling reveals involvement of the cerebral cortex in Parkinson's disease, 16th International Congress of Neuropathology, Publisher: BLACKWELL PUBLISHING, Pages: S8-S8, ISSN: 1015-6305
Duke DC, Moran LB, Kalaitzakis ME, et al., 2006, Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson's disease, NEUROGENETICS, Vol: 7, Pages: 139-148, ISSN: 1364-6745
- Author Web Link
- Cite
- Citations: 73
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.